US Patent

US9050348 — Dermal delivery device

Formulation · Assigned to Agile Therapeutics Inc · Expires 2028-07-10 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a dermal delivery device that causes cumulative irritation and/or detachment over a seven-day period.

USPTO Abstract

A transdermal drug delivery device is disclosed. Over an extended wear period, the device causes cumulative moderate irritation plus significant irritation of less than 5% and/or achieves a meaningful degree of detachment over a seven day period of less than 20%.

Drugs covered by this patent

Patent Metadata

Patent number: US9050348
Jurisdiction: US
Classification: Formulation
Expires: 2028-07-10
Drug substance claim: No
Drug product claim: Yes
Assignee: Agile Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.